Journal article
Plasmodium falciparum and Plasmodium vivax genotypes and efficacy of intermittent preventive treatment in Papua New Guinea
C Barnadas, N Senn, J Iga, L Timinao, S Javati, E Malau, P Rarau, JC Reeder, P Siba, H Karunajeewa, PA Zimmerman, TM Davis, I Mueller
Antimicrobial Agents and Chemotherapy | AMER SOC MICROBIOLOGY | Published : 2014
DOI: 10.1128/AAC.03323-14
Abstract
Intermittent preventive treatment of infants (IPTi) reduces early childhood malaria-related morbidity. While genotypic drug resistance markers have proven useful in predicting the efficacy of antimalarial drugs in case management, there are few equivalent data relating to their protective efficacy when used as IPTi. The present data from an IPTi trial in Papua New Guinea demonstrate how these markers can predict protective efficacy of IPTi for both Plasmodium falciparum and Plasmodium vivax.
Grants
Awarded by Bill & Melinda Gates Foundation
Awarded by Australian National Health and Medical Research Council
Awarded by NHMRC
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
This study was supported by grants from the Bill & Melinda Gates Foundation (grant no. 34678) and the Australian National Health and Medical Research Council (grant no. 1010203). T.M.D. was supported by an NHMRC Practitioner Fellowship (no. 1058260), I.M. by an NHMRC Senior Research Fellowship (no. 1043345), and H.K. by an NHMRC Career Development Fellowship (no. 1064772).